{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:49Z","timestamp":1792788709898,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54512-7","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:23:35Z","timestamp":1735554215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Julia","family":"Paczkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7345-5106","authenticated-orcid":false,"given":"Emma L.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Weirather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3548-913X","authenticated-orcid":false,"given":"Naomi","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billie A.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima Zumla","family":"Cader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mandato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Calabretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gali","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee N.","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-1603","authenticated-orcid":false,"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-7339","authenticated-orcid":false,"given":"Xiaole Shirley","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-6897","authenticated-orcid":false,"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"54512_CR1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger, M. A. & Kuppers, R. Molecular biology of Hodgkin lymphoma. Leukemia 35, 968\u2013981 (2021).","journal-title":"Leukemia"},{"key":"54512_CR2","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B cell lymphoma. Blood 116, 3268\u20133277 (2010).","journal-title":"Blood"},{"key":"54512_CR3","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34, 2690\u20132697 (2016).","journal-title":"J. Clin. Oncol."},{"key":"54512_CR4","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand, K. et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 3, 4065\u20134080 (2019).","journal-title":"Blood Adv."},{"key":"54512_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/bloodadvances.2023012353","volume":"8","author":"SM Ansell","year":"2024","unstructured":"Ansell, S. M. et al. Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274. Blood Adv. 8, 829\u2013831 (2024).","journal-title":"Blood Adv."},{"key":"54512_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.2022019386","volume":"142","author":"P Armand","year":"2023","unstructured":"Armand, P. et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma. Blood 142, 878\u2013886 (2023).","journal-title":"Blood"},{"key":"54512_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer, M. G. M. et al. Major histocompatibility complex Class II and programmed death Ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin Lymphoma. J. Clin. Oncol. 36, 942\u2013950 (2018).","journal-title":"J. Clin. Oncol."},{"key":"54512_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand, P. et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 134, 22\u201329 (2019).","journal-title":"Blood"},{"key":"54512_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani, R. H. et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 138, 427\u2013438 (2021).","journal-title":"Blood"},{"key":"54512_CR10","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz, A. J. et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin Lymphoma. J. Clin. Oncol. 39, 3109\u20133117 (2021).","journal-title":"J. Clin. Oncol."},{"key":"54512_CR11","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","volume":"37","author":"R Ramchandren","year":"2019","unstructured":"Ramchandren, R. et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin Lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J. Clin. Oncol. 37, 1997\u20132007 (2019).","journal-title":"J. Clin. Oncol."},{"key":"54512_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","volume":"137","author":"PB Allen","year":"2021","unstructured":"Allen, P. B. et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 137, 1318\u20131326 (2021).","journal-title":"Blood"},{"key":"54512_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Brockelmann","year":"2020","unstructured":"Brockelmann, P. J. et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic hodgkin lymphoma: the randomized phase 2 german hodgkin study group NIVAHL trial. JAMA Oncol. 6, 872\u2013880 (2020).","journal-title":"JAMA Oncol."},{"key":"54512_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hon.3163_5","volume":"41","author":"AF Herrera","year":"2023","unstructured":"Herrera, A. F. et al. Nivoumab (N)-AVD improves progression-free survival compared to brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL): Results of SWOG S1826. Hematolog. Oncol. 41, 33\u201335 (2023).","journal-title":"Hematolog. Oncol."},{"key":"54512_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera, A. F. et al. Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s Lymphoma. N. Engl. J. Med. 391, 1379\u20131389 (2024).","journal-title":"N. Engl. J. Med."},{"key":"54512_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel, J. et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125, 1061\u20131072 (2015).","journal-title":"Blood"},{"key":"54512_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","volume":"4","author":"MG Roemer","year":"2016","unstructured":"Roemer, M. G. et al. Classical Hodgkin Lymphoma with reduced beta2M\/MHC Class I expression is associated with inferior outcome independent of 9p24.1 Status. Cancer Immunol. Res. 4, 910\u2013916 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"54512_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","volume":"132","author":"FZ Cader","year":"2018","unstructured":"Cader, F. Z. et al. Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T cell-rich and exhausted T-effector microenvironment. Blood 132, 825\u2013836 (2018).","journal-title":"Blood"},{"key":"54512_CR19","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey, C. D. et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130, 2420\u20132430 (2017).","journal-title":"Blood"},{"key":"54512_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin lymphoma. N. Engl. J. Med. 362, 875\u2013885 (2010).","journal-title":"N. Engl. J. Med."},{"key":"54512_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","volume":"10","author":"T Aoki","year":"2020","unstructured":"Aoki, T. et al. Single-cell transcriptome analysis reveals disease-defining T cell subsets in the tumor microenvironment of classic Hodgkin Lymphoma. Cancer Discov. 10, 406\u2013421 (2020).","journal-title":"Cancer Discov."},{"key":"54512_CR22","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","volume":"26","author":"FZ Cader","year":"2020","unstructured":"Cader, F. Z. et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat. Med 26, 1468\u20131479 (2020).","journal-title":"Nat. Med"},{"key":"54512_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/cyto.a.23724","volume":"95","author":"CM Mousset","year":"2019","unstructured":"Mousset, C. M. et al. Comprehensive phenotyping of T cells using flow cytometry. Cytom. A 95, 647\u2013654 (2019).","journal-title":"Cytom. A"},{"key":"54512_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12464-3","volume":"10","author":"PA Szabo","year":"2019","unstructured":"Szabo, P. A. et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat. Commun. 10, 4706 (2019).","journal-title":"Nat. Commun."},{"key":"54512_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779961","volume":"12","author":"M Lyu","year":"2021","unstructured":"Lyu, M. et al. Dissecting the landscape of activated CMV-stimulated CD4+ T cells in humans by linking single-cell RNA-Seq with T cell receptor sequencing. Front Immunol. 12, 779961 (2021).","journal-title":"Front Immunol."},{"key":"54512_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-018-0001-y","volume":"18","author":"T van den Broek","year":"2018","unstructured":"van den Broek, T., Borghans, J. A. M. & van Wijk, F. The full spectrum of human naive T cells. Nat. Rev. Immunol. 18, 363\u2013373 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"54512_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/ni.2362","volume":"13","author":"M Kuwahara","year":"2012","unstructured":"Kuwahara, M. et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat. Immunol. 13, 778\u2013786 (2012).","journal-title":"Nat. Immunol."},{"key":"54512_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529\u2013542 (2014).","journal-title":"Immunity"},{"key":"54512_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-018-0637-x","volume":"11","author":"P Fang","year":"2018","unstructured":"Fang, P. et al. Immune cell subset differentiation and tissue inflammation. J. Hematol. Oncol. 11, 97 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"54512_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867189","volume":"13","author":"M Cenerenti","year":"2022","unstructured":"Cenerenti, M., Saillard, M., Romero, P. & Jandus, C. The Era of Cytotoxic CD4 T cells. Front Immunol. 13, 867189 (2022).","journal-title":"Front Immunol."},{"key":"54512_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fcell.2020.00384","volume":"8","author":"L Zhou","year":"2020","unstructured":"Zhou, L. et al. Single-Cell RNA-Seq analysis uncovers distinct functional human NKT cell sub-populations in peripheral blood. Front Cell Dev. Biol. 8, 384 (2020).","journal-title":"Front Cell Dev. Biol."},{"key":"54512_CR32","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1818488116","volume":"116","author":"G Pizzolato","year":"2019","unstructured":"Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVdelta1 and TCRVdelta2 gammadelta T lymphocytes. Proc. Natl Acad. Sci. USA 116, 11906\u201311915 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54512_CR33","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","volume":"20","author":"DI Godfrey","year":"2019","unstructured":"Godfrey, D. I., Koay, H. F., McCluskey, J. & Gherardin, N. A. The biology and functional importance of MAIT cells. Nat. Immunol. 20, 1110\u20131128 (2019).","journal-title":"Nat. Immunol."},{"key":"54512_CR34","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/s41590-023-01575-1","volume":"24","author":"LC Garner","year":"2023","unstructured":"Garner, L. C. et al. Single-cell analysis of human MAIT cell transcriptional, functional and clonal diversity. Nat. Immunol. 24, 1565\u20131578 (2023).","journal-title":"Nat. Immunol."},{"key":"54512_CR35","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1073\/pnas.1114981109","volume":"109","author":"SY Liu","year":"2012","unstructured":"Liu, S. Y., Sanchez, D. J., Aliyari, R., Lu, S. & Cheng, G. Systematic identification of Type I and type II interferon-induced antiviral factors. Proc. Natl Acad. Sci. USA 109, 4239\u20134244 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54512_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.05.001","volume":"43","author":"S Lukhele","year":"2019","unstructured":"Lukhele, S., Boukhaled, G. M. & Brooks, D. G. Type I interferon signaling, regulation and gene stimulation in chronic virus infection. Semin. Immunol. 43, 101277 (2019).","journal-title":"Semin. Immunol."},{"key":"54512_CR37","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibrian","year":"2017","unstructured":"Cibrian, D. & Sanchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol. 47, 946\u2013953 (2017).","journal-title":"Eur. J. Immunol."},{"key":"54512_CR38","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.3389\/fimmu.2019.03100","volume":"10","author":"D Shevyrev","year":"2019","unstructured":"Shevyrev, D. & Tereshchenko, V. Treg heterogeneity, function, and homeostasis. Front Immunol. 10, 3100 (2019).","journal-title":"Front Immunol."},{"key":"54512_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","volume":"49","author":"MG Roncarolo","year":"2018","unstructured":"Roncarolo, M. G., Gregori, S., Bacchetta, R., Battaglia, M. & Gagliani, N. The biology of T regulatory Type 1 cells and their therapeutic application in immune-mediated diseases. Immunity 49, 1004\u20131019 (2018).","journal-title":"Immunity"},{"key":"54512_CR40","first-page":"265","volume":"11","author":"A Chao","year":"1984","unstructured":"Chao, A. Nonparametric estimation of the number of classes in a population. Scand. J. Stat. 11, 265\u2013270 (1984).","journal-title":"Scand. J. Stat."},{"key":"54512_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2307\/2531532","volume":"43","author":"A Chao","year":"1993","unstructured":"Chao, A., Ma, M. & Yang, M. Stopping rules and estimation for recapture debugging with unequal failure rates. Biometrics 43, 783\u2013791 (1993).","journal-title":"Biometrics"},{"key":"54512_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm.3773","volume":"21","author":"C Linnemann","year":"2015","unstructured":"Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med 21, 81\u201385 (2015).","journal-title":"Nat. Med"},{"key":"54512_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910293","volume":"11","author":"M Zuazo","year":"2019","unstructured":"Zuazo, M. et al. Functional systemic CD4 immunity is required for clinical responses to PD-L1\/PD-1 blockade therapy. EMBO Mol. Med 11, e10293 (2019).","journal-title":"EMBO Mol. Med"},{"key":"54512_CR44","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","volume":"4","author":"J Nagasaki","year":"2020","unstructured":"Nagasaki, J. et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 4, 4069\u20134082 (2020).","journal-title":"Blood Adv."},{"key":"54512_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586907","volume":"11","author":"M Zuazo","year":"2020","unstructured":"Zuazo, M. et al. Systemic CD4 immunity as a Key Contributor to PD-L1\/PD-1 Blockade Immunotherapy Efficacy. Front Immunol. 11, 586907 (2020).","journal-title":"Front Immunol."},{"key":"54512_CR46","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/2326-6066.CIR-19-0574","volume":"8","author":"H Kagamu","year":"2020","unstructured":"Kagamu, H. et al. CD4(+) T cell immunity in the peripheral blood correlates with response to Anti-PD-1 therapy. Cancer Immunol. Res. 8, 334\u2013344 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"54512_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/iid3.85","volume":"3","author":"K Weatherly","year":"2015","unstructured":"Weatherly, K. et al. Functional profile of S100A4-deficient T cells. Immun. Inflamm. Dis. 3, 431\u2013444 (2015).","journal-title":"Immun. Inflamm. Dis."},{"key":"54512_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri3442","volume":"13","author":"D Masopust","year":"2013","unstructured":"Masopust, D. & Schenkel, J. M. The integration of T cell migration, differentiation and function. Nat. Rev. Immunol. 13, 309\u2013320 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"54512_CR49","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708\u2013712 (1999).","journal-title":"Nature"},{"key":"54512_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15543-y","volume":"11","author":"E Cano-Gamez","year":"2020","unstructured":"Cano-Gamez, E. et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4(+) T cells to cytokines. Nat. Commun. 11, 1801 (2020).","journal-title":"Nat. Commun."},{"key":"54512_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109078","volume":"241","author":"F Wang","year":"2022","unstructured":"Wang, F., Cheng, F. & Zheng, F. Stem cell like memory T cells: a new paradigm in cancer immunotherapy. Clin. Immunol. 241, 109078 (2022).","journal-title":"Clin. Immunol."},{"key":"54512_CR52","doi-asserted-by":"crossref","unstructured":"Aoki, T. et al. Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 118, e2105822118 (2021).","DOI":"10.1073\/pnas.2105822118"},{"key":"54512_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3389\/fendo.2019.00471","volume":"10","author":"MG Kazanietz","year":"2019","unstructured":"Kazanietz, M. G., Durando, M. & Cooke, M. CXCL13 and its receptor CXCR5 in cancer: inflammation, immune response, and beyond. Front Endocrinol. (Lausanne) 10, 471 (2019).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"54512_CR54","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1182\/blood-2011-01-332106","volume":"118","author":"J Saez de Guinoa","year":"2011","unstructured":"Saez de Guinoa, J., Barrio, L., Mellado, M. & Carrasco, Y. R. CXCL13\/CXCR5 signaling enhances BCR-triggered B cell activation by shaping cell dynamics. Blood 118, 1560\u20131569 (2011).","journal-title":"Blood"},{"key":"54512_CR55","doi-asserted-by":"crossref","unstructured":"Ager, C. R. et al. KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. J. Immunother. Cancer 11, e006782 (2023).","DOI":"10.1136\/jitc-2023-006782"},{"key":"54512_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51, 27\u201341 (2019).","journal-title":"Immunity"},{"key":"54512_CR57","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","volume":"38","author":"LM Snell","year":"2017","unstructured":"Snell, L. M., McGaha, T. L. & Brooks, D. G. Type I interferon in chronic virus infection and cancer. Trends Immunol. 38, 542\u2013557 (2017).","journal-title":"Trends Immunol."},{"key":"54512_CR58","doi-asserted-by":"publisher","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","volume":"41","author":"I Rusinova","year":"2013","unstructured":"Rusinova, I. et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040\u2013D1046 (2013).","journal-title":"Nucleic Acids Res."},{"key":"54512_CR59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dominguez, R. & Silva-Santos, B. The emerging roles of gammadelta T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"54512_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen, Z., Prinz, I., Dechanet-Merville, J., Silva-Santos, B. & Kuball, J. Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19, 169\u2013184 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"54512_CR61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","volume":"613","author":"NL de Vries","year":"2023","unstructured":"de Vries, N. L. et al. gammadelta T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743\u2013750 (2023).","journal-title":"Nature"},{"key":"54512_CR62","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/bloodadvances.2019000699","volume":"4","author":"SL Smith","year":"2020","unstructured":"Smith, S. L. et al. Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. Blood Adv. 4, 1388\u20131406 (2020).","journal-title":"Blood Adv."},{"key":"54512_CR63","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.it.2022.01.003","volume":"43","author":"D Morgan","year":"2022","unstructured":"Morgan, D. & Tergaonkar, V. Unraveling B cell trajectories at single cell resolution. Trends Immunol. 43, 210\u2013229 (2022).","journal-title":"Trends Immunol."},{"key":"54512_CR64","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhang, L., Yu, C., Yang, X. F. & Wang, H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2, (2014).","DOI":"10.1186\/2050-7771-2-1"},{"key":"54512_CR65","doi-asserted-by":"crossref","unstructured":"Villani, A. C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).","DOI":"10.1126\/science.aah4573"},{"key":"54512_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11947-7","volume":"10","author":"C Yang","year":"2019","unstructured":"Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019).","journal-title":"Nat. Commun."},{"key":"54512_CR67","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2021.09.002","volume":"54","author":"B Kramer","year":"2021","unstructured":"Kramer, B. et al. Early IFN-alpha signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54, 2650\u20132669.e2614 (2021).","journal-title":"Immunity"},{"key":"54512_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09670-4","volume":"10","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. Single-cell trajectories reconstruction, exploration and mapping of omics data with STREAM. Nat. Commun. 10, 1903 (2019).","journal-title":"Nat. Commun."},{"key":"54512_CR69","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cyto.a.24507","volume":"101","author":"R Carsetti","year":"2022","unstructured":"Carsetti, R. et al. Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions. Cytom. A 101, 131\u2013139 (2022).","journal-title":"Cytom. A"},{"key":"54512_CR70","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41592-021-01142-2","volume":"18","author":"L Song","year":"2021","unstructured":"Song, L. et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat. Methods 18, 627\u2013630 (2021).","journal-title":"Nat. Methods"},{"key":"54512_CR71","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","volume":"27","author":"SS Kim","year":"2021","unstructured":"Kim, S. S. et al. Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin. Cancer Res. 27, 6075\u20136082 (2021).","journal-title":"Clin. Cancer Res."},{"key":"54512_CR72","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"54512_CR73","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"54512_CR74","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"54512_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61356-w","volume":"10","author":"BJ Ravenhill","year":"2020","unstructured":"Ravenhill, B. J., Soday, L., Houghton, J., Antrobus, R. & Weekes, M. P. Comprehensive cell surface proteomics defines markers of classical, intermediate and non-classical monocytes. Sci. Rep. 10, 4560 (2020).","journal-title":"Sci. Rep."},{"key":"54512_CR76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin, M. & Bigley, V. Human dendritic cell subsets: an update. Immunology 154, 3\u201320 (2018).","journal-title":"Immunology"},{"key":"54512_CR77","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2014.09.014","volume":"41","author":"M Chittezhath","year":"2014","unstructured":"Chittezhath, M. et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 41, 815\u2013829 (2014).","journal-title":"Immunity"},{"key":"54512_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl7482","volume":"7","author":"DE Sanin","year":"2022","unstructured":"Sanin, D. E. et al. A common framework of monocyte-derived macrophage activation. Sci. Immunol. 7, eabl7482 (2022).","journal-title":"Sci. Immunol."},{"key":"54512_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo4652","volume":"7","author":"P Loke","year":"2022","unstructured":"Loke, P. & Lin, J. D. Redefining inflammatory macrophage phenotypes across stages and tissues by single-cell transcriptomics. Sci. Immunol. 7, eabo4652 (2022).","journal-title":"Sci. Immunol."},{"key":"54512_CR80","doi-asserted-by":"crossref","unstructured":"Caronni, N. et al. IL-1beta(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415\u2013422 (2023).","DOI":"10.1038\/s41586-023-06685-2"},{"key":"54512_CR81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 14, 22\u201329 (2012).","journal-title":"J. Mol. Diagn."},{"key":"54512_CR82","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-0716-0623-0_18","volume":"2148","author":"M Millar","year":"2020","unstructured":"Millar, M. Mixed multiplex staining: automated RNAscope and OPAL for multiple targets. Methods Mol. Biol. 2148, 277\u2013298 (2020).","journal-title":"Methods Mol. Biol."},{"key":"54512_CR83","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","volume":"54","author":"K Mulder","year":"2021","unstructured":"Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883\u20131900.e1885 (2021).","journal-title":"Immunity"},{"key":"54512_CR84","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"54512_CR85","doi-asserted-by":"crossref","unstructured":"Raggi, F. & Bosco, M. C. Targeting mononuclear phagocyte receptors in cancer immunotherapy: new perspectives of the triggering receptor expressed on myeloid cells (TREM-1). Cancers (Basel) 12, 1337 (2020).","DOI":"10.3390\/cancers12051337"},{"key":"54512_CR86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.30593","volume":"70","author":"Q Wu","year":"2019","unstructured":"Wu, Q. et al. Blocking Triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology 70, 198\u2013214 (2019).","journal-title":"Hepatology"},{"key":"54512_CR87","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4049\/jimmunol.1700129","volume":"199","author":"M Boro","year":"2017","unstructured":"Boro, M. & Balaji, K. N. CXCL1 and CXCL2 regulate NLRP3 inflammasome activation via G-protein-coupled receptor CXCR2. J. Immunol. 199, 1660\u20131671 (2017).","journal-title":"J. Immunol."},{"key":"54512_CR88","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","volume":"50","author":"A Mantovani","year":"2019","unstructured":"Mantovani, A., Dinarello, C. A., Molgora, M. & Garlanda, C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50, 778\u2013795 (2019).","journal-title":"Immunity"},{"key":"54512_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00154-7","volume":"5","author":"JH Jang","year":"2021","unstructured":"Jang, J. H., Kim, D. H. & Surh, Y. J. Dynamic roles of inflammasomes in inflammatory tumor microenvironment. NPJ Precis Oncol. 5, 18 (2021).","journal-title":"NPJ Precis Oncol."},{"key":"54512_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/srep36107","volume":"6","author":"B Guo","year":"2016","unstructured":"Guo, B., Fu, S., Zhang, J., Liu, B. & Li, Z. Targeting inflammasome\/IL-1 pathways for cancer immunotherapy. Sci. Rep. 6, 36107 (2016).","journal-title":"Sci. Rep."},{"key":"54512_CR91","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"54512_CR92","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693\u2013698 (2020).","journal-title":"Nat. Med."},{"key":"54512_CR93","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus, S. et al. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1(\u2212)CD8(+) Tumor-Infiltrating T Cells. Immunity 50, 181\u2013194.e186 (2019).","journal-title":"Immunity"},{"key":"54512_CR94","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/bjh.18762","volume":"201","author":"J Grund","year":"2023","unstructured":"Grund, J. et al. Low B cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma. Br. J. Haematol. 201, 1097\u20131102 (2023).","journal-title":"Br. J. Haematol."},{"key":"54512_CR95","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.humpath.2013.06.006","volume":"44","author":"CS Tudor","year":"2013","unstructured":"Tudor, C. S. et al. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum. Pathol. 44, 2475\u20132486 (2013).","journal-title":"Hum. Pathol."},{"key":"54512_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111384","volume":"40","author":"BP Keenan","year":"2022","unstructured":"Keenan, B. P. et al. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell Rep. 40, 111384 (2022).","journal-title":"Cell Rep."},{"key":"54512_CR97","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","volume":"18","author":"J Hou","year":"2021","unstructured":"Hou, J., Karin, M. & Sun, B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat. Rev. Clin. Oncol. 18, 261\u2013279 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"54512_CR98","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","volume":"27","author":"DH Aggen","year":"2021","unstructured":"Aggen, D. H. et al. Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses. Clin. Cancer Res. 27, 608\u2013621 (2021).","journal-title":"Clin. Cancer Res."},{"key":"54512_CR99","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov, I. et al. Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl Acad. Sci. USA 116, 1361\u20131369 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54512_CR100","doi-asserted-by":"publisher","first-page":"237ra267","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra267 (2014).","journal-title":"Sci. Transl. Med."},{"key":"54512_CR101","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele, C. W. et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832\u2013845 (2016).","journal-title":"Cancer Cell"},{"key":"54512_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862125","volume":"13","author":"AM Ghallab","year":"2022","unstructured":"Ghallab, A. M., Eissa, R. A. & El Tayebi, H. M. CXCR2 small-molecule antagonist combats chemoresistance and enhances immunotherapy in triple-negative breast cancer. Front Pharm. 13, 862125 (2022).","journal-title":"Front Pharm."},{"key":"54512_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27108-8","volume":"12","author":"A Rogic","year":"2021","unstructured":"Rogic, A. et al. High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer. Nat. Commun. 12, 6889 (2021).","journal-title":"Nat. Commun."},{"key":"54512_CR104","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura, T. et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 212, 1043\u20131059 (2015).","journal-title":"J. Exp. Med."},{"key":"54512_CR105","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222\u2013225 (2011).","journal-title":"Nature"},{"key":"54512_CR106","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet, M. J., Michielin, O. & Migliorini, D. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402\u2013421 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"54512_CR107","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","volume":"28","author":"D Di Mitri","year":"2019","unstructured":"Di Mitri, D. et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 28, 2156\u20132168.e2155 (2019).","journal-title":"Cell Rep."},{"key":"54512_CR108","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ccell.2023.03.004","volume":"41","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell 41, 693\u2013710.e698 (2023).","journal-title":"Cancer Cell"},{"key":"54512_CR109","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"54512_CR110","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"54512_CR111","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"54512_CR112","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1214\/22-AOAS1689","volume":"17","author":"S Tiberi","year":"2023","unstructured":"Tiberi, S., Crowell, H. L., Samartsidis, P., Weber, L. M. & Robinson, M. D. Distinct: a novel approach to differential distribution analyses. Ann. Appl. Stat. 17, 1681\u20131700, 1620 (2023).","journal-title":"Ann. Appl. Stat."},{"key":"54512_CR113","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci."},{"key":"54512_CR114","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"54512_CR115","doi-asserted-by":"publisher","unstructured":"Popov, A. et al. Immunomind\/immunarch: Immunarch 0.9.1 (0.9.1). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.3367200 (2024).","DOI":"10.5281\/zenodo.3367200"},{"key":"54512_CR116","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N. Engl. J. Med 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med"},{"key":"54512_CR117","doi-asserted-by":"crossref","unstructured":"Alessi, J. V. et al. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J. Immunother. Cancer 9, e003536 (2021).","DOI":"10.1136\/jitc-2021-003536"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54512-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54512-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54512-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T12:03:00Z","timestamp":1735560180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54512-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54512"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54512-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T. is a full-time employee of Astra Zeneca. K.L. is a full-time employee of PathAI. F.Z.C. is a full-time employee of AstraZeneca. J.O. is a full-time employee of Bristol Myers Squibb. P.A. consults for Merck, Bristol Myers Squibb, A.D.C. Therapeutics, GenMab, Enterome, Genentech\/Roche, ATB Therapeutics, Foresight Diagnostics, AstraZeneca, MSD, Tessa Therapeutics, Regeneron, Xencor, and receives institutional research funding from Merck, Bristol Myers Squibb, Genentech\/Roche, KITE\/Gilead, Adaptive Biotechnologies, IGM, AstraZeneca, MSD, Aamed Therapeutics and honoraria from Merck. S.J.R. receives institutional research funding from Bristol Myers Squibb, KITE\/Gilead and is an advisory board member of Immunitas Therapeutics. X.S.L. is the founder and CEO of GV20 Therapeutics, LLC. M.A.S. has received research funding from Bristol Myers Squibb, AstraZeneca, Bayer Abbvie, Genentech and Novartis and has served on advisory boards for Bristol Myers Squibb and AstraZeneca. The remaining authors declare no competing financial interests. No authors have non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10740"}}